July 7, 2020 / 11:27 AM / a month ago

BRIEF-Regeneron Announces Manufacturing And Supply Agreement For BARDA And U.S. Department Of Defense For REGN-COV2 Anti-Viral Antibody Cocktail

July 7 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT FOR BARDA AND U.S. DEPARTMENT OF DEFENSE FOR REGN-COV2 ANTI-VIRAL ANTIBODY COCKTAIL

* REGENERON PHARMACEUTICALS INC - CO AWARDED $450 MILLION CONTRACT TO MANUFACTURE AND SUPPLY REGN-COV2

* REGENERON PHARMACEUTICALS INC - REGENERON BEGAN SCALING UP MANUFACTURING OF REGN-COV2 AT BUSINESS RISK IN SPRING OF 2020.

* REGENERON PHARMACEUTICALS INC - AGREEMENT COVERS A FIXED NUMBER OF BULK LOTS THAT ARE INTENDED TO BE COMPLETED IN FALL OF 2020

* REGENERON PHARMACEUTICALS INC - INITIAL DOSES MAY BE READY AS EARLY AS END OF SUMMER.

* REGENERON PHARMACEUTICALS- AGREEMENT COVERS FIXED NO. OF BULK LOTS THAT ARE INTENDED TO COMPLETE IN FALL OF 2020, & FILL/FINISH, STORAGE ACTIVITIES

* REGENERON - IF EUA OR PRODUCT APPROVAL IS GRANTED, GOV’T HAS COMMITTED TO MAKING DOSES FROM THE LOTS AVAILABLE TO AMERICAN PEOPLE AT ‘NO COST’

* REGENERON PHARMACEUTICALS- CONTINUES TO WORK TO MAXIMIZE MANUFACTURING CAPACITY OF REGN-COV2 WITHIN REGENERON, WITH POTENTIAL PARTNERS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below